Form 4: Atara Biotherapeutics EVP, CFO and COO Eric J. Hyllengren Reports Sale of Common Stock

Eric J. Hyllengren, EVP, CFO and COO of Atara Biotherapeutics, sold 1,211 shares of common stock on March 3, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On March 3, 2025, Eric J. Hyllengren, the EVP, CFO, and COO of Atara Biotherapeutics, sold 1,211 shares of the company's common stock.
• The sale was executed to satisfy tax withholding obligations associated with the vesting of previously granted restricted stock units.
• The shares were sold at a weighted average price of $6.997 per share.
• Following the transaction, Hyllengren directly owns 56,231 shares of Atara Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an executive's stock sale for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. This sale is related to tax obligations and may not reflect a change in the executive's long-term outlook for the company.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial condition.

Key Dates